Navigation Links
ULURU Inc. Reports First Quarter 2008 Financial Results
Date:5/12/2008

ADDISON, Texas, May 12 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today reported financial results for the first quarter ended March 31, 2008.

For the quarter ended March 31, 2008, the net loss attributable to common stockholders was $1,815,000, or $0.03 per share, compared to a net loss of $847,000, or $0.01 per share, for the corresponding period in 2007. The first quarter 2008 net loss was impacted by non-cash expenses of $497,000, which included stock option expense, amortization, and depreciation of $208,000, $269,000 and $20,000, respectively, whereas the first quarter 2007 net loss included non-cash expenses of $385,000, which included stock option expense, amortization, and depreciation of $103,000, $265,000 and $17,000, respectively.

Income Statement

Revenues for the first quarter of 2008 were $256,000, compared with $384,000 for the same period last year. The decrease of $127,000 in revenues is comprised of a decrease in licensing of $124,000 and a decrease in sponsored research of $190,000, as both of the prior year revenue components were non-recurring. These two decreases were partially offset by an increase of $20,000 in royalty income associated with our Zindaclin(R) product and $167,000 in Aphthasol(R) product sales to our domestic distributor.

Total costs and expenses, including amortization and depreciation, increased by $753,000 in the first quarter of 2008 to $2,196,000, compared with the corresponding period in 2007 where total costs and expenses, including amortization and depreciation, were $1,443,000. The overall expense increase is primarily attributable to increases in Research and Development of $310,000, increases in General and Administrative of $298,000, and Cost of Goods Sold
'/>"/>

SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
4. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. Reports Third Quarter 2007 Results
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
8. ULURU Inc. Announces Odd-Lot Buy Back Offer
9. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
10. Novadaq Reports Financial Results for the First Quarter of 2008
11. Isis Reports Financial Results and Highlights for First Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 01, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... to their industry leading Scientific Advisory Board. LRF’s volunteer Scientific Advisory Board (SAB), ...
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. Surya Challa of Chesapeake Vein Center ... The Hampton Roads Show to discuss non-invasive CoolSculpting . On the show, Dr. ... , CoolSculpting fat reduction utilizes Cryolipolysis to literally freeze stubborn, unwanted fat away ...
(Date:7/1/2015)... ... July 01, 2015 , ... During the first week ... Sales Training and Development) and Chuck Corso (Associate Sales Trainer) participated in the ... LTEN brings together learning and development professionals from more than 300 life sciences ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Convoy of ... community celebration in the Twin Cities on Saturday, August 1, at Spring Lake Park ... community will provide more than $1 million worth of goods and services including free ...
(Date:7/1/2015)... ... 01, 2015 , ... Element Blue ™, a leading ... it has received trademark protection for its SensorInsight® computer software platform. SensorInsight® is ... multiple sources providing an environment where users can view and compare real-time and ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 2Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4
... a munificent $15 million to assist Lebanon to rise ... According to Foreign Minister Alexander// Downer, Australia has managed ... during the post-conflict time, to help rebuild a country ... will support restoring health infrastructure and providing adequate access ...
... "enormous silence" in India around adolescent sexual and reproductive ... of parents, in-laws, spouses// and elders, says a new ... (ICRW) and partners. ,More than half ... many adolescents, particularly unmarried girls, suffer serious reproductive health ...
... of more than three glasses of red wine a week ... cancer, according to research presented at// the 71st Annual Scientific ... Based on the results of this study, researchers suspect the ... a key role. Resveratrol is an anti-fungal chemical that occurs ...
... a supplement of cinnamon extract on a daily basis ... a condition associated// with increased risk of type-2 diabetes ... obesity, hypertension, and unstable glucose and insulin metabolism and ... current study was presented this month at the 47th ...
... third case of carrot juice-linked botulism has been reported in ... drank U.S.-produced carrot juice earlier// this month. ,According ... from Quebec while the first two are from Toronto. It ... ,The affected products are produced in California and sold ...
... studies have revealed that college students put on several pounds in ... college students gain an average of 15// pounds in their freshman ... to put on weight. ,The first study was conducted ... According to the study results, both girls and guys gained an ...
Cached Medicine News:Health News:Intervention Needed to Break 'Silence' on Reproductive Health 2Health News:Intervention Needed to Break 'Silence' on Reproductive Health 3Health News:Cinnamon extract in reduction of risk of metabolic syndrome 2
(Date:7/1/2015)... , July 1, 2015 According ... Adhesives Market by Product (Natural & Synthetic, Fibrin, Collagen, ... Cosmetic Surgery) - Global Forecast to 2020", published by ... estimated to reach $2.64 Billion by 2020, growing at ... to 2020). Browse 119 market T ...
(Date:7/1/2015)... YORK, Pa. , July 1, 2015  Unilife ... developer, manufacturer and supplier of injectable drug delivery systems, ... been amended as of June 30, 2015. This amendment ... least $20 million in cash receipts from customers during ... no other adjustments to any of the terms of ...
(Date:7/1/2015)... CAESAREA, Israel , July 1, 2015 /PRNewswire/ ... Diabetes Management Solution, today announced the appointment of Todd ... for the U.S.  Durniak brings to LabStyle over ... leadership, most recently as the Vice President and ... Insulet focused on delivering insulin supplies through durable ...
Breaking Medicine Technology:Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 3Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 4Unilife and OrbiMed Amend Debt Financing Agreement 2Unilife and OrbiMed Amend Debt Financing Agreement 3LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 2LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 3LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
... test is a rapid immunochromatographic screening test ... cruzi. It can be used with ... employs a unique combination of a specific ... dye particles, and antigens which are bound ...
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
... Medtronic Subcutaneous Lead System Model ... with the use of the ... Improved SQ design and implant ... fast and easy procedure, and ...
... defibrillator lead features a patented ... flexibility and maneuverability of a ... physician who prefers a lead ... SPL lead also promotes low ...
Medicine Products: